This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Scandion Oncology 将来の成長
Future 基準チェック /26
主要情報
-43.4%
収益成長率
-43.4%
EPS成長率
| Biotechs 収益成長 | 46.4% |
| 収益成長率 | 81.1% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | n/a |
今後の成長に関する最新情報
更新なし
Recent updates
更新なし
業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2023 | 1 | -109 | N/A | N/A | 1 |
| 12/31/2022 | 1 | -55 | N/A | N/A | 1 |
| 3/31/2022 | N/A | -56 | -57 | -56 | N/A |
| 12/31/2021 | N/A | -52 | -50 | -50 | N/A |
| 9/30/2021 | N/A | -43 | -48 | -48 | N/A |
| 6/30/2021 | N/A | -31 | -34 | -34 | N/A |
| 3/31/2021 | N/A | -22 | -24 | -24 | N/A |
| 12/31/2020 | N/A | -17 | -17 | -17 | N/A |
| 9/30/2020 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -14 | -14 | -14 | N/A |
| 3/31/2020 | N/A | -14 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -12 | -10 | -10 | N/A |
| 9/30/2019 | N/A | -17 | -21 | -21 | N/A |
| 6/30/2019 | N/A | -12 | -16 | -16 | N/A |
| 3/31/2019 | N/A | -10 | -15 | -15 | N/A |
| 12/31/2018 | N/A | -8 | -13 | -13 | N/A |
| 9/30/2018 | N/A | -4 | -3 | -3 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: SCOL BTA is forecast to remain unprofitable over the next 3 years.
収益対市場: SCOL BTA is forecast to remain unprofitable over the next 3 years.
高成長収益: SCOL BTA is forecast to remain unprofitable over the next 3 years.
収益対市場: SCOL BTA's revenue (81.1% per year) is forecast to grow faster than the Swedish market (9.3% per year).
高い収益成長: SCOL BTA's revenue (81.1% per year) is forecast to grow faster than 20% per year.
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: Insufficient data to determine if SCOL BTA's Return on Equity is forecast to be high in 3 years time